Skip to content
2000
image of Netherton Syndrome Perspectives

Abstract

Netherton syndrome (NS), also known as Comèl-Netherton syndrome, is a rare disorder of cornification resulting from pathogenic variants in the Kazal type 5 () gene encoding serine protease inhibitor LEKTI. NS is characterized by the triad of congenital ichthyosiform erythroderma (CIE)/ichthyosis linearis circumflexa (ILC), trichorrhexis invaginata (TI), and atopic diathesis. Due to the severity of pathogenesis and variability in clinical presentations, the management of NS poses significant therapeutic challenges, which often require a multidisciplinary approach. Current treatment modalities predominantly consist of topical interventions and supportive measures. With an improved understanding of NS pathophysiology, emerging literature has suggested novel systemic therapeutic options for NS, which include repurposed biologics like targeted inhibitors and intravenous immunoglobulins, but there remains a paucity of literature regarding their clinical outcomes. Although often cited among dermatologists and allergists, the condition is rare in Hong Kong and Singapore, and most physicians have not managed any case. This review suggests that NS may be underestimated clinically. We aim to raise awareness for clinicians in the specific clinical characteristics and pathophysiology of NS to decide tailor-made treatment plans and improve patient outcomes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpr/10.2174/0115733963361849250611072347
2025-06-19
2025-10-30

  • From This Site

    /content/journals/cpr/10.2174/0115733963361849250611072347
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Smith D.L. Smith J.G. Wong S.W. deShazo R.D. Netherton’s syndrome: A syndrome of elevated IgE and characteristic skin and hair findings. J. Allergy Clin. Immunol. 1995 95 1 116 123 10.1016/S0091‑6749(95)70159‑1 7822652
    [Google Scholar]
  2. Dodeja A. Meshram K. Pande S. Oke M. Borkar M. Oral tofacitinib therapy for the effective management of netherton syndrome. Cureus 2023 15 5 e39349 10.7759/cureus.39349 37351253
    [Google Scholar]
  3. Saleem H.M.K. Shahid M.F. Shahbaz A. Sohail A. Shahid M.A. Sachmechi I. Netherton syndrome: A case report and review of literature. Cureus 2018 10 7 e3070 10.7759/cureus.3070 30280066
    [Google Scholar]
  4. Saleem H.M.K. Shahid M.F. Shahbaz A. Sohail A. Netherton syndrome: A genotype-phenotype review. Mol Diagn Ther 2017 21 137 152 10.1007/s40291‑016‑0243‑y.
    [Google Scholar]
  5. Petrova E. Hovnanian A. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opin. Orphan Drugs 2020 8 11 455 487 10.1080/21678707.2020.1857724
    [Google Scholar]
  6. Geyer A.S. Ratajczak P. Pol-Rodriguez M. Millar W.S. Garzon M. Richard G. Netherton syndrome with extensive skin peeling and failure to thrive due to a homozygous frameshift mutation in SPINK5. Dermatology 2005 210 4 308 314 10.1159/000084755 15942217
    [Google Scholar]
  7. Barbati F. Giovannini M. Oranges T. Lodi L. Barni S. Novembre E. Baldo E. Cristofolini M. Stagi S. Ricci S. Mori F. Filippeschi C. Azzari C. Indolfi G. Netherton syndrome in children: Management and future perspectives. Front Pediatr. 2021 9 645259 10.3389/fped.2021.645259 34041207
    [Google Scholar]
  8. Cheng T.S Giam Y.C. Failure to grow and infections in a baby with Netherton syndrome Netherton. Hong Kong J. Dermatol. Venereol. 2010 18 4
    [Google Scholar]
  9. Xu M. Shi Y. Lin L. Wang L. Zhu X. Xiong J. Yin J. Qi Q. Yang W. The role of SPINK5 mutation distribution in phenotypes of Netherton syndrome. Front. Genet. 2025 16 1475054 10.3389/fgene.2025.1475054 39931731
    [Google Scholar]
  10. Alpigiani M.G. Salvati P. Schiaffino M.C. Occella C. Castiglia D. Covaciu C. Lorini R. A new SPINK5 mutation in a patient with Netherton syndrome: A case report. Pediatr. Dermatol. 2012 29 4 521 522 10.1111/j.1525‑1470.2011.01525.x 21692842
    [Google Scholar]
  11. Deraison C. Bonnart C. Lopez F. Besson C. Robinson R. Jayakumar A. Wagberg F. Brattsand M. Hachem J.P. Leonardsson G. Hovnanian A. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 2007 18 9 3607 3619 10.1091/mbc.e07‑02‑0124 17596512
    [Google Scholar]
  12. Brattsand M. Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 1999 274 42 30033 30040 10.1074/jbc.274.42.30033 10514489
    [Google Scholar]
  13. Borgoño C.A. Michael I.P. Komatsu N. Jayakumar A. Kapadia R. Clayman G.L. Sotiropoulou G. Diamandis E.P. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 2007 282 6 3640 3652 10.1074/jbc.M607567200 17158887
    [Google Scholar]
  14. Nouwen A.E.M. Schappin R. Nguyen N.T. Ragamin A. Bygum A. Bodemer C. Dalm V.A.S.H. Pasmans S.G.M.A. Outcomes of systemic treatment in children and adults with Netherton Syndrome: A systematic review. Front. Immunol. 2022 13 864449 10.3389/fimmu.2022.864449 35464459
    [Google Scholar]
  15. Lacroix M. Lacaze-Buzy L. Furio L. Tron E. Valari M. Van der Wier G. Bodemer C. Bygum A. Bursztejn A.C. Gaitanis G. Paradisi M. Stratigos A. Weibel L. Deraison C. Hovnanian A. Clinical expression and new SPINK5 splicing defects in Netherton syndrome: Unmasking a frequent founder synonymous mutation and unconventional intronic mutations. J. Invest. Dermatol. 2012 132 3 575 582 10.1038/jid.2011.366 22089833
    [Google Scholar]
  16. Leung A.K.C. Barankin B. Leong K.F. An 8-year-old child with delayed diagnosis of netherton syndrome. Case Rep. Pediatr. 2018 2018 1 4 10.1155/2018/9434916 29527381
    [Google Scholar]
  17. Srinivas S. Hiremagalore R. Suryanarayan S. Budamakuntala L. Netherton syndrome with pili torti. Int. J. Trichology 2013 5 4 225 226 10.4103/0974‑7753.130424 24778540
    [Google Scholar]
  18. Netherton syndrome. 2023 Available from: https://www.uptodate.com/contents/netherton-syndrome
  19. Volc S. Maier L. Gritsch A. Aichelburg M.C. Volc-Platzer B. Successful treatment of Netherton syndrome with ustekinumab in a 15‐year‐old girl. Br. J. Dermatol. 2020 183 1 165 167 10.1111/bjd.18892 31977080
    [Google Scholar]
  20. Burk C. Hu S. Lee C. Connelly E.A. Netherton syndrome and trichorrhexis invaginata: A novel diagnostic approach. Pediatr. Dermatol. 2008 25 2 287 288 10.1111/j.1525‑1470.2008.00663.x 18429812
    [Google Scholar]
  21. Bittencourt M.de. Moure E.R. Pies O.T. Trichoscopy as a diagnostic tool in trichorrhexis invaginata and Netherton syndrome. An Bras Dermatol 2015 90 114 116 10.1590/abd1806‑4841.20153011
    [Google Scholar]
  22. Powell J. Dawber R.P.R. Ferguson D.J.P. Griffiths W.A.D. Netherton’s syndrome: Increased likelihood of diagnosis by examining eyebrow hairs. Br. J. Dermatol. 1999 141 3 544 546 10.1046/j.1365‑2133.1999.03056.x 10583065
    [Google Scholar]
  23. Goujon E. Beer F. Fraitag S. Hovnanian A. Vabres P. ‘Matchstick’ eyebrow hairs: A dermoscopic clue to the diagnosis of Netherton syndrome. J. Eur. Acad. Dermatol. Venereol. 2010 24 6 740 741 10.1111/j.1468‑3083.2009.03459.x 19840201
    [Google Scholar]
  24. Herz-Ruelas M.E. Chavez-Alvarez S. Garza-Chapa J.I. Ocampo-Candiani J. Cab-Morales V.A. Kubelis-López D.E. Herz-RuelasME Netherton syndrome: Case report and review of the literature. Skin Appendage Disord. 2021 7 5 346 350 10.1159/000514699
    [Google Scholar]
  25. Leclerc-Mercier S. Bodemer C. Furio L. Hadj-Rabia S. de Peufeilhoux L. Weibel L. Bursztejn A.C. Bourrat E. Ortonne N. Molina T.J. Hovnanian A. Fraitag S. Skin biopsy in netherton syndrome. Am. J. Dermatopathol. 2016 38 2 83 91 10.1097/DAD.0000000000000425 26825155
    [Google Scholar]
  26. Boussofara L. Ghariani N. Denguezli M. Netherton’s syndrome: The importance of eyebrow hair. Dermatol. Online J. 2007 13 3 21 18328215
    [Google Scholar]
  27. Flora A. Smith A. Netherton’s syndrome: A case of two male siblings diagnosed in adulthood. Case Rep. Dermatol. 2020 12 1 64 69 10.1159/000507359 32355487
    [Google Scholar]
  28. Guerra L. Fortugno P. Pedicelli C. Mazzanti C. Proto V. Zambruno G. Castiglia D. Ichthyosis Linearis Circumflexa as the only clinical manifestation of netherton syndrome. Acta Derm. Venereol. 2015 95 6 720 724 10.2340/00015555‑2075 25710899
    [Google Scholar]
  29. Oji V. Traupe H. Ichthyosis. Am. J. Clin. Dermatol. 2009 10 6 351 364 10.2165/11311070‑000000000‑00000 19824737
    [Google Scholar]
  30. Vahlquist A. Gånemo A. Virtanen M. Congenital ichthyosis: An overview of current and emerging therapies. Acta Derm. Venereol. 2008 88 1 4 14 10.2340/00015555‑0415 18176742
    [Google Scholar]
  31. Schmid M.H. Korting H.C. The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers. Dermatology 1995 191 4 276 280 10.1159/000246568 8573921
    [Google Scholar]
  32. Purnamawati S. Indrastuti N. Danarti R. Saefudin T. The role of moisturizers in addressing various kinds of dermatitis: A review. Clin. Med. Res. 2017 15 3-4 75 87 10.3121/cmr.2017.1363 29229630
    [Google Scholar]
  33. Mazereeuw-Hautier J. Vahlquist A. Traupe H. Bygum A. Amaro C. Aldwin M. Audouze A. Bodemer C. Bourrat E. Diociaiuti A. Dolenc-Voljc M. Dreyfus I. El Hachem M. Fischer J. Gånemo A. Gouveia C. Gruber R. Hadj-Rabia S. Hohl D. Jonca N. Ezzedine K. Maier D. Malhotra R. Rodriguez M. Ott H. Paige D.G. Pietrzak A. Poot F. Schmuth M. Sitek J.C. Steijlen P. Wehr G. Moreen M. O’Toole E.A. Oji V. Hernandez-Martin A. Management of congenital ichthyoses: European guidelines of care, part one. Br. J. Dermatol. 2019 180 2 272 281 10.1111/bjd.17203 30216406
    [Google Scholar]
  34. Schneider I. Sebök B. Kosztolányi G. Szekeres G. Comel-Netherton syndrome: Evolution of manifestation in a 20-year follow-up and phenotypic overlap with peeling skin syndrome type B. Acta Derm. Venereol. 2000 80 3 209 210 10.1080/000155500750043005 10954215
    [Google Scholar]
  35. Nguyen V. Cunningham B.B. Eichenfield L.F. Alió A.B. Buka R.L. Treatment of ichthyosiform diseases with topically applied tazarotene: Risk of systemic absorption. J. Am. Acad. Dermatol. 2007 57 5 Suppl. S123 S125 10.1016/j.jaad.2006.05.028 17938025
    [Google Scholar]
  36. Fleckman P. Newell B.D. van Steensel M.A. Yan A.C. Topical treatment of ichthyoses. Dermatol. Ther. 2013 26 1 16 25 10.1111/j.1529‑8019.2012.01526.x 23384017
    [Google Scholar]
  37. Pontone M. Giovannini M. Filippeschi C. Oranges T. Pedaci F.A. Mori F. Barni S. Barbati F. Consonni F. Indolfi G. Lodi L. Azzari C. Ricci S. Hovnanian A. Biological treatments for pediatric Netherton syndrome. Front Pediatr. 2022 10 1074243 10.3389/fped.2022.1074243 36619513
    [Google Scholar]
  38. Yalcin A.D. A case of netherton syndrome: Successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol. Immunotoxicol. 2016 38 2 162 166 10.3109/08923973.2015.1115518 26592187
    [Google Scholar]
  39. Galdo G. Fania L. A Netherton syndrome case report: Response to dupilumab treatment. Dermatol. Ther. 2022 35 11 e15862 10.1111/dth.15862 36175157
    [Google Scholar]
  40. Martin-García C. Godoy E. Cabrera A. Cañueto J. Muñoz-Bellido F.J. Perez-Pazos J. Dávila I. Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature. Int. J. Immunopathol. Pharmacol. 2023 37 03946320231172881 10.1177/03946320231172881 37200480
    [Google Scholar]
  41. Valette C. Ofaiche J. Severino M. Mazereeuw-HautierJ. Ann. Dermatol. Venereol. 2020 147 36 40 10.1016/j.annder.2019.09.003 31653452
    [Google Scholar]
  42. Gutfreund K. Bienias W. Szewczyk A. Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol. Alergol. 2013 3 3 165 169 10.5114/pdia.2013.35619 24278069
    [Google Scholar]
  43. Luger T. Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007 215 Suppl. 1 45 54 10.1159/000102119 18174692
    [Google Scholar]
  44. Saif G.B. Al-Khenaizan S. SaifGBin Netherton syndrome: Successful use of topical tacrolimus and pimecrolimus in four siblings. Int. J. Dermatol. 2007 46 3 290 294 10.1111/j.1365‑4632.2006.02956.x 17343588
    [Google Scholar]
  45. Ume A.C. Wenegieme T.Y. Williams C.R. Calcineurin inhibitors: A double-edged sword. Am. J. Physiol. Renal Physiol. 2021 320 3 F336 F341 10.1152/ajprenal.00262.2020 33225712
    [Google Scholar]
  46. Beljan G. Traupe H. Metze D. Sunderkötter C. Comèl-Netherton syndrome with bacterial superinfection. Hautarzt 2003 54 12 1198 1202 10.1007/s00105‑003‑0572‑8 14634751
    [Google Scholar]
  47. Lee H. Shin J.U.. Lee K.H. A case of netherton syndrome responsive to 1% topical pimecrolimus cream. Korean J. Dermatol 2014 52 12 926
    [Google Scholar]
  48. Allen A. Siegfried E. Silverman R. Williams M.L. Elias P.M. Szabo S.K. Korman N.J. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 2001 137 6 747 750 11405764
    [Google Scholar]
  49. Trémezaygues L. Reichrath J. Vitamin D analogs in the treatment of psoriasis. Dermatoendocrinol 2011 3 3 180 186 10.4161/derm.17534 22110777
    [Google Scholar]
  50. Thomas J. Parimalam K. Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med. Ther. 2016 7 25 38 10.2147/PHMT.S75834 29388608
    [Google Scholar]
  51. DiGiovanna J.J. Mauro T. Milstone L.M. Schmuth M. Toro J.R. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol. Ther. 2013 26 1 26 38 10.1111/j.1529‑8019.2012.01527.x 23384018
    [Google Scholar]
  52. Singer R. Çopur M. Yüksel E.N. Kocatürk E. Erhan S.Ş. Ichthyosis linearis circumflexa in a child. Response to narrowband UVB therapy. J. Dermatol. Case Rep. 2015 9 4 110 112 10.3315/jdcr.2015.1214 26848320
    [Google Scholar]
  53. Nagata T. Netherton’s syndrome which responded to photochemotherapy. Dermatology 1980 161 1 51 56 10.1159/000250330 7398977
    [Google Scholar]
  54. Wong T. Hsu L. Liao W. Phototherapy in psoriasis: A review of mechanisms of action. J. Cutan. Med. Surg. 2013 17 1 6 12 10.2310/7750.2012.11124 23364144
    [Google Scholar]
  55. Moutran R. Maatouk I. Development of multiple nevi and lentigines in a child with N etherton’s syndrome treated with narrowband ultraviolet B phototherapy. Int. J. Dermatol. 2015 54 7 e271 e273 10.1111/ijd.12797 25782441
    [Google Scholar]
  56. Brown F.S. Burnett J.W. Robinson H.M. Jr Cutaneous carcinoma following psoralen and long-wave ultraviolet radiation (PUVA) therapy for psoriasis. J. Am. Acad. Dermatol. 1980 2 5 393 395 10.1016/S0190‑9622(80)80362‑8 6892920
    [Google Scholar]
  57. Renner E.D. Hartl D. Rylaarsdam S. Young M.L. Monaco-Shawver L. Kleiner G. Markert M.L. Stiehm E.R. Belohradsky B.H. Upton M.P. Torgerson T.R. Orange J.S. Ochs H.D. Comèl-Netherton syndrome defined as primary immunodeficiency. J. Allergy Clin. Immunol. 2009 124 3 536 543 10.1016/j.jaci.2009.06.009 19683336
    [Google Scholar]
  58. Bonilla F.A. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc. 2016 37 6 426 431 10.2500/aap.2016.37.3987 27931296
    [Google Scholar]
  59. Othy S. Hegde P. Topçu S. Sharma M. Maddur M.S. Lacroix-Desmazes S. Bayry J. Kaveri S.V. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J. Immunol. 2013 190 9 4535 4541 10.4049/jimmunol.1201965 23526819
    [Google Scholar]
  60. Zhang Z. Pan C. Wei R. Li H. Yang Y. Chen J. Li M. Yao Z. Netherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large‐sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin. Mol. Genet. Genomic Med. 2021 9 3 e1600 10.1002/mgg3.1600 33452875
    [Google Scholar]
  61. Ragamin A. Nouwen A.E.M. Dalm V.A.S.H. van Mierlo M.M.F. Lincke C.R. Pasmans S.G.M.A. Treatment experiences with intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton syndrome: A case series. Dermatology 2023 239 1 72 80 10.1159/000525987 35998563
    [Google Scholar]
  62. Zelieskova M. Banovcin P. Kozar M. Kozarova A. Nudzajova Z. Jesenak M. A novel SPINK5 mutation and successful subcutaneous immunoglobulin replacement therapy in a child with Netherton syndrome. Pediatr. Dermatol. 2020 37 6 1202 1204 10.1111/pde.14318 32767583
    [Google Scholar]
  63. Gallagher J.L. Patel N.C. Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants. J. Clin. Immunol. 2012 32 3 474 476 10.1007/s10875‑011‑9645‑0 22228569
    [Google Scholar]
  64. Bilgic Eltan S. Keskin O. Deveci M.F. Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment. North. Clin. Istanb. 2021 9 3 228 234 10.14744/nci.2020.16870 36199862
    [Google Scholar]
  65. Barbieux C. Bonnet des Claustres M. Fahrner M. Petrova E. Tsoi L.C. Gouin O. Leturcq F. Nicaise-Roland P. Bole C. Béziat V. Bourrat E. Schilling O. Gudjonsson J.E. Hovnanian A. Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses. J. Allergy Clin. Immunol. 2022 149 4 1358 1372 10.1016/j.jaci.2021.08.024 34543653
    [Google Scholar]
  66. Herzum A. Occella C. Gariazzo L. Formigoni C. Viglizzo G. Dupilumab in paediatric Netherton syndrome: Can we do better? Australas. J. Dermatol. 2023 64 3 e305 e307 10.1111/ajd.14097 37279014
    [Google Scholar]
  67. Özkaya E. Günay M.B. Babuna Kobaner G. Keskinkaya Z. Gökalp M.O. Long‐term dupilumab therapy in Netherton syndrome with severe atopic manifestations: Case report and review of the literature. Australas. J. Dermatol. 2023 64 2 272 277 10.1111/ajd.13986 36745433
    [Google Scholar]
  68. Inaba Y. Kanazawa N. Muraoka K. Yariyama A. Kawaguchi A. Kunimoto K. Kaminaka C. Yamamoto Y. Tsujioka K. Yoshida A. Yanagi T. Jinnin M. Dupilumab improves pruritus in Netherton syndrome: A case study. Children 2022 9 3 310 10.3390/children9030310 35327681
    [Google Scholar]
  69. Joosten M.D.W. Clabbers J.M.K. Jonca N. Mazereeuw-Hautier J. Gostyński A.H. New developments in the molecular treatment of ichthyosis: Review of the literature. Orphanet J. Rare Dis. 2022 17 1 269 10.1186/s13023‑022‑02430‑6 35840979
    [Google Scholar]
  70. Wiegmann H. Valentin F. Tarinski T. Liebau E. Loser K. Traupe H. Oji V. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: Implications for targeted therapy of Netherton syndrome. Br. J. Dermatol. 2019 181 5 999 1008 10.1111/bjd.17820 30801672
    [Google Scholar]
  71. Furio L. Hovnanian A. Netherton syndrome: Defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol. Chem. 2014 395 9 945 958 10.1515/hsz‑2014‑0137 25153381
    [Google Scholar]
  72. Zani M.B. Sant’Ana A.M. Tognato R.C. Chagas J.R. Puzer L. Human tissue kallikreins-related peptidases are targets for the treatment of skin desquamation diseases. Front. Med. (Lausanne) 2022 8 777619 10.3389/fmed.2021.777619 35356049
    [Google Scholar]
  73. Di W.L. Larcher F. Semenova E. Talbot G.E. Harper J.I. Del Rio M. Thrasher A.J. Qasim W. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 2011 19 2 408 416 10.1038/mt.2010.201 20877344
    [Google Scholar]
  74. Di W.L. Mellerio J.E. Bernadis C. Harper J. Abdul-Wahab A. Ghani S. Chan L. Martinez-Queipo M. Hara H. McNicol A.M. Farzaneh F. McGrath J. Thrasher A. Qasim W. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum. Gene Ther. Clin. Dev. 2013 24 4 182 190 10.1089/humc.2013.195 24329107
    [Google Scholar]
  75. Wang Y. Song H. Yu L. Wu N. Zheng X. Liang B. Wang P. A novel mutation in SPINK5 gene underlies a case of atypical Netherton syndrome. Front. Genet. 2022 13 943264 10.3389/fgene.2022.943264 36159989
    [Google Scholar]
  76. Chao S-C. Richard G. Lee J.Y-Y. Netherton syndrome: Report of two Taiwanese siblings with staphylococcal scalded skin syndrome and mutation of SPINK 5. Br. J. Dermatol. 2005 152 1 159 165 10.1111/j.1365‑2133.2005.06337.x 15656819
    [Google Scholar]
  77. Lefferdink R. Rangel S.M. Chima M. Ibler E. Pavel A.B. Kim H. Wu B. Abu-Zayed H. Wu J. Jackson K. Singer G. Choate K.A. Guttman-Yassky E. Paller A.S. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults. Arch. Dermatol. Res. 2022 315 2 305 315 10.1007/s00403‑022‑02325‑3 35218370
    [Google Scholar]
  78. Samuelov L. Shehadeh W. Sarig O. Gat A. Matz H. Sprecher E. Ustekinumab therapy for Netherton syndrome. J. Dermatol. 2023 50 4 494 499 10.1111/1346‑8138.16645 36419401
    [Google Scholar]
  79. Yan S. Wu X. Jiang J. Yu S. Fang X. Yang H. Bai X. Wang H. Luo X. Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation. Front. Immunol. 2022 13 1054422 10.3389/fimmu.2022.1054422 36569942
    [Google Scholar]
  80. Cicek F. Cekic S. Kilic S.S. Infliximab therapy in an infant with Netherton syndrome. Pediatr. Dermatol. 2021 38 3 714 716 10.1111/pde.14590 33890311
    [Google Scholar]
  81. Barbieux C. Bonnet des Claustres M. de la Brassinne M. Bricteux G. Bagot M. Bourrat E. Hovnanian A. Duality of Netherton syndrome manifestations and response to ixekizumab. J. Am. Acad. Dermatol. 2021 84 5 1476 1480 10.1016/j.jaad.2020.07.054 32692997
    [Google Scholar]
  82. Luchsinger I. Knöpfel N. Theiler M. Bonnet des Claustres M. Barbieux C. Schwieger-Briel A. Brunner C. Donghi D. Buettcher M. Meier-Schiesser B. Hovnanian A. Weibel L. Secukinumab therapy for netherton syndrome. JAMA Dermatol. 2020 156 8 907 911 10.1001/jamadermatol.2020.1019 32459284
    [Google Scholar]
  83. Yan A.C. Honig P.J. Ming M.E. Weber J. Shah K.N. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: Results from an exploratory study. Arch. Dermatol. 2010 146 1 57 62 10.1001/archdermatol.2009.326 20083693
    [Google Scholar]
  84. Blanchard S.K. Prose N.S. Successful use of secukinumab in Netherton syndrome. JAAD Case Rep. 2020 6 6 577 578 10.1016/j.jdcr.2020.04.025 32518812
    [Google Scholar]
  85. Süßmuth K. Traupe H. Loser K. Ständer S. Kessel C. Wittkowski H. Oji V. Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling. J. Eur. Acad. Dermatol. Venereol. 2021 35 2 e152 e155 10.1111/jdv.16883 32810299
    [Google Scholar]
  86. Murase C. Takeichi T. Taki T. Yoshikawa T. Suzuki A. Ogi T. Suga Y. Akiyama M. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome. J. Dermatol. Sci. 2021 102 2 126 129 10.1016/j.jdermsci.2021.03.003 33773888
    [Google Scholar]
  87. Huang Q. Tian X. Liang J.Y. Shao L. Zhang J. Liang Y. Huang T. Zhang X. Liu Y. Effective treatment of Netherton syndrome in children with dupilumab: A case report and review of the literature. Int. J. Dermatol. 2023 62 7 946 949 10.1111/ijd.16593 36694447
    [Google Scholar]
  88. Murashkin N.N. Opryatin L.A. Bridan-Rostovskaya A.S. Pavlova E.S. Ivanov R.A. Avetisyan K.O. Kulikov K.A. Results of combined pathogenetic therapy in netherton syndrome: Clinical case. Curr. Paediatr. 2023 22 5 433 442 10.15690/vsp.v22i5.2621
    [Google Scholar]
  89. Bai J. Chen X. Qiao J. Fang H. Treatment of Netherton syndrome with spesolimab. J. Eur. Acad. Dermatol. Venereol. 2025 39 3 e261 e262 10.1111/jdv.20244 39073211
    [Google Scholar]
  90. Sun C. Chen Y. Treatment of netherton syndrome in pediatrics with upadacitinib. Altern. Ther. Health Med. 2025 31 1 266 269 38607195
    [Google Scholar]
/content/journals/cpr/10.2174/0115733963361849250611072347
Loading
Netherton Syndrome Perspectives
Bentham Science Publishers ; https://doi.org/10.2174/0115733963361849250611072347
/content/journals/cpr/10.2174/0115733963361849250611072347
/content/journals/cpr/10.2174/0115733963361849250611072347
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: congenital ichthyosiform erythroderma ; trichorrhexis invaginata ; Atopic diathesis ; ichthyosis linearis circumflexa

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test